Amarin Corporation Plc (AMRN) 1.18 $AMRN
What One Ought to Know in the Healthcare Sector: New Research on Amarin, Amedica, Amedisys, American CareSource, and AS&E
PR Newswire - Thu Feb 12, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ANCI: 3.10 (-0.20), AMRN: 1.18 (unch), ASEI: 56.82 (+0.30), AMED: 28.62 (+0.16), AMDA: 0.65 (+0.01)
Amarin Up 7.1%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Wed Feb 11, 12:43PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 7.1% to $1.21 on 1.8x average daily volume. Amarin has traded 2.0 million shares thus far today, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.5%) and outperformed the S&P 500 (7.1% to the S&P's -0.4%) during today's trading.
AMRN: 1.18 (unch)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 1.18 (unch), FOLD: 8.36 (-0.11), MEIP: 5.00 (-0.04), EXEL: 2.48 (+0.20)
Amarin's Vascepa Ends January With Flat Prescription Growth, But Still Trending Up
Clinically Sound Investor - at Seeking Alpha - Mon Feb 09, 2:02PM CST
AMRN: 1.18 (unch)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
5 Stocks Under $10 Set to Soar: J.C. Penney, Amarin and More
at The Street - Thu Feb 05, 5:00AM CST
These under-$10 stocks look ready to trade much higher from current levels. Here's how to play them.
NRP: 7.86 (-0.45), XNET: 7.93 (+0.23), AMRN: 1.18 (unch), NEOT: 6.69 (-0.04), JCP: 8.05 (+0.14)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Amarin's Reduced Cash Burn Makes Dilution Less Likely
Clinically Sound Investor - at Seeking Alpha - Mon Jan 26, 11:32AM CST
AMRN: 1.18 (unch)
Update: Amarin Estimates A $120 Million Year-End Cash Balance
Elephant Analytics - at Seeking Alpha - Wed Jan 14, 7:11AM CST
AMRN: 1.18 (unch)
Amarin to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Marketwired - Mon Jan 05, 6:00AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, at 11:00 a.m. PT.
JPM: 59.67 (+0.10), AMRN: 1.18 (unch)
Amarin: Kowa Co-Promotion Agreement May Be Boosting Sales
Elephant Analytics - at Seeking Alpha - Mon Jan 05, 3:52AM CST
AMRN: 1.18 (unch)
Good News: Vascepa Kept Its Place On National Formularies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 17, 1:33PM CST
AMRN: 1.18 (unch)
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 3.84 (unch), NVAX: 8.80 (+0.40), AMRN: 1.18 (unch), AEZS: 0.53 (unch), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Amarin Corporation: Upside Becomes Clearer While The Path To The Finish Line Remains Murky
Outsized Analytics - at Seeking Alpha - Sun Dec 07, 8:47AM CST
AMRN: 1.18 (unch), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Amarin to Present at the 25th Annual Oppenheimer Healthcare Conference
Marketwired - Thu Dec 04, 6:02AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 25th Annual Oppenheimer Healthcare Conference in New York City on Thursday, December 11, at 3:20 p.m. ET.
AMRN: 1.18 (unch)
Amarin: The Silence Of The Lamb
Scrying Biotech - at Seeking Alpha - Tue Dec 02, 9:08AM CST
AMRN: 1.18 (unch)
Why Amarin Corporation PLC Stock Flew 37% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 1:27PM CST
AMRN data by YCharts What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing therapies that are designed to treat cardiovascular diseases, rocketed higher by 37% in November, according to data from S&P...
AMRN: 1.18 (unch)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 2.13 (+0.18), AMRN: 1.18 (unch), JCP: 8.05 (+0.14), SNSS: 2.28 (+0.01), SWHC: 12.63 (-0.20)
What One Ought to Know in the Healthcare Sector: New Research on Amarin, Amedica, Amedisys, American CareSource, and AS&E
PR Newswire - Thu Feb 12, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ANCI: 3.10 (-0.20), AMRN: 1.18 (unch), ASEI: 56.82 (+0.30), AMED: 28.62 (+0.16), AMDA: 0.65 (+0.01)
Amarin Up 7.1%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Wed Feb 11, 12:43PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 7.1% to $1.21 on 1.8x average daily volume. Amarin has traded 2.0 million shares thus far today, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.5%) and outperformed the S&P 500 (7.1% to the S&P's -0.4%) during today's trading.
AMRN: 1.18 (unch)
4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
at The Street - Tue Feb 10, 1:01PM CST
Keep these under-$10 biotech stocks on your breakout trading radar.
AMRN: 1.18 (unch), FOLD: 8.36 (-0.11), MEIP: 5.00 (-0.04), EXEL: 2.48 (+0.20)
Amarin's Vascepa Ends January With Flat Prescription Growth, But Still Trending Up
Clinically Sound Investor - at Seeking Alpha - Mon Feb 09, 2:02PM CST
AMRN: 1.18 (unch)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
5 Stocks Under $10 Set to Soar: J.C. Penney, Amarin and More
at The Street - Thu Feb 05, 5:00AM CST
These under-$10 stocks look ready to trade much higher from current levels. Here's how to play them.
NRP: 7.86 (-0.45), XNET: 7.93 (+0.23), AMRN: 1.18 (unch), NEOT: 6.69 (-0.04), JCP: 8.05 (+0.14)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Amarin's Reduced Cash Burn Makes Dilution Less Likely
Clinically Sound Investor - at Seeking Alpha - Mon Jan 26, 11:32AM CST
AMRN: 1.18 (unch)
Update: Amarin Estimates A $120 Million Year-End Cash Balance
Elephant Analytics - at Seeking Alpha - Wed Jan 14, 7:11AM CST
AMRN: 1.18 (unch)
Amarin to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Marketwired - Mon Jan 05, 6:00AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, at 11:00 a.m. PT.
JPM: 59.67 (+0.10), AMRN: 1.18 (unch)
Amarin: Kowa Co-Promotion Agreement May Be Boosting Sales
Elephant Analytics - at Seeking Alpha - Mon Jan 05, 3:52AM CST
AMRN: 1.18 (unch)
Good News: Vascepa Kept Its Place On National Formularies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 17, 1:33PM CST
AMRN: 1.18 (unch)
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 3.84 (unch), NVAX: 8.80 (+0.40), AMRN: 1.18 (unch), AEZS: 0.53 (unch), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Amarin Corporation: Upside Becomes Clearer While The Path To The Finish Line Remains Murky
Outsized Analytics - at Seeking Alpha - Sun Dec 07, 8:47AM CST
AMRN: 1.18 (unch), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Amarin to Present at the 25th Annual Oppenheimer Healthcare Conference
Marketwired - Thu Dec 04, 6:02AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 25th Annual Oppenheimer Healthcare Conference in New York City on Thursday, December 11, at 3:20 p.m. ET.
AMRN: 1.18 (unch)
Amarin: The Silence Of The Lamb
Scrying Biotech - at Seeking Alpha - Tue Dec 02, 9:08AM CST
AMRN: 1.18 (unch)
Why Amarin Corporation PLC Stock Flew 37% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 1:27PM CST
AMRN data by YCharts What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing therapies that are designed to treat cardiovascular diseases, rocketed higher by 37% in November, according to data from S&P...
AMRN: 1.18 (unch)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 2.13 (+0.18), AMRN: 1.18 (unch), JCP: 8.05 (+0.14), SNSS: 2.28 (+0.01), SWHC: 12.63 (-0.20)
